Regenxbio Q3 EPS $(0.62) Beats $(1.26) Estimate, Sales $9.162M Miss $10.868M Estimate
Benzinga Newsdesk 6 hours ago
NewsEarningsEarnings BeatsEarnings Misses
Regenxbio (NASDAQ:RGNX) reported quarterly losses of $(0.62) per share which beat the analyst consensus estimate of $(1.26) by 50.79 percent. This is a 48.33 percent increase over losses of $(1.20) per share from the
Regenxbio (NASDAQ:RGNX) reported quarterly losses of $(0.62) per share which beat the analyst consensus estimate of $(1.26) by 50.79 percent. This is a 48.33 percent increase over losses of $(1.20) per share from the same period last year. The company reported quarterly sales of $9.162 million which missed the analyst consensus estimate of $10.868 million by 15.70 percent. This is a 69.19 percent decrease over sales of $29.733 million the same period last year.